Cargando…
Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794779/ https://www.ncbi.nlm.nih.gov/pubmed/34728775 http://dx.doi.org/10.1038/s41366-021-00996-y |
_version_ | 1784640896747175936 |
---|---|
author | Kantonen, Tatu Pekkarinen, Laura Karjalainen, Tomi Bucci, Marco Kalliokoski, Kari Haaparanta-Solin, Merja Aarnio, Richard Dickens, Alex M. von Eyken, Annie Laitinen, Kirsi Houttu, Noora Kirjavainen, Anna K. Helin, Semi Hirvonen, Jussi Rönnemaa, Tapani Nuutila, Pirjo Nummenmaa, Lauri |
author_facet | Kantonen, Tatu Pekkarinen, Laura Karjalainen, Tomi Bucci, Marco Kalliokoski, Kari Haaparanta-Solin, Merja Aarnio, Richard Dickens, Alex M. von Eyken, Annie Laitinen, Kirsi Houttu, Noora Kirjavainen, Anna K. Helin, Semi Hirvonen, Jussi Rönnemaa, Tapani Nuutila, Pirjo Nummenmaa, Lauri |
author_sort | Kantonen, Tatu |
collection | PubMed |
description | BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the brain, potential obesity-promoting mechanisms in the central nervous system have remained elusive. In this triple-tracer positron emission tomography study, we investigated whether brain insulin signaling, μ-opioid receptors (MORs) and cannabinoid CB(1) receptors (CB(1)Rs) are associated with risk for developing obesity. METHODS: Subjects were 41 young non-obese males with variable obesity risk profiles. Obesity risk was assessed by subjects’ physical exercise habits, body mass index and familial risk factors, including parental obesity and T2D. Brain glucose uptake was quantified with [(18)F]FDG during hyperinsulinemic euglycemic clamp, MORs were quantified with [(11)C]carfentanil and CB(1)Rs with [(18)F]FMPEP-d(2). RESULTS: Subjects with higher obesity risk had globally increased insulin-stimulated brain glucose uptake (19 high-risk subjects versus 19 low-risk subjects), and familial obesity risk factors were associated with increased brain glucose uptake (38 subjects) but decreased availability of MORs (41 subjects) and CB(1)Rs (36 subjects). CONCLUSIONS: These results suggest that the hereditary mechanisms promoting obesity may be partly mediated via insulin, opioid and endocannabinoid messaging systems in the brain. |
format | Online Article Text |
id | pubmed-8794779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87947792022-02-07 Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability Kantonen, Tatu Pekkarinen, Laura Karjalainen, Tomi Bucci, Marco Kalliokoski, Kari Haaparanta-Solin, Merja Aarnio, Richard Dickens, Alex M. von Eyken, Annie Laitinen, Kirsi Houttu, Noora Kirjavainen, Anna K. Helin, Semi Hirvonen, Jussi Rönnemaa, Tapani Nuutila, Pirjo Nummenmaa, Lauri Int J Obes (Lond) Article BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the brain, potential obesity-promoting mechanisms in the central nervous system have remained elusive. In this triple-tracer positron emission tomography study, we investigated whether brain insulin signaling, μ-opioid receptors (MORs) and cannabinoid CB(1) receptors (CB(1)Rs) are associated with risk for developing obesity. METHODS: Subjects were 41 young non-obese males with variable obesity risk profiles. Obesity risk was assessed by subjects’ physical exercise habits, body mass index and familial risk factors, including parental obesity and T2D. Brain glucose uptake was quantified with [(18)F]FDG during hyperinsulinemic euglycemic clamp, MORs were quantified with [(11)C]carfentanil and CB(1)Rs with [(18)F]FMPEP-d(2). RESULTS: Subjects with higher obesity risk had globally increased insulin-stimulated brain glucose uptake (19 high-risk subjects versus 19 low-risk subjects), and familial obesity risk factors were associated with increased brain glucose uptake (38 subjects) but decreased availability of MORs (41 subjects) and CB(1)Rs (36 subjects). CONCLUSIONS: These results suggest that the hereditary mechanisms promoting obesity may be partly mediated via insulin, opioid and endocannabinoid messaging systems in the brain. Nature Publishing Group UK 2021-11-02 2022 /pmc/articles/PMC8794779/ /pubmed/34728775 http://dx.doi.org/10.1038/s41366-021-00996-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kantonen, Tatu Pekkarinen, Laura Karjalainen, Tomi Bucci, Marco Kalliokoski, Kari Haaparanta-Solin, Merja Aarnio, Richard Dickens, Alex M. von Eyken, Annie Laitinen, Kirsi Houttu, Noora Kirjavainen, Anna K. Helin, Semi Hirvonen, Jussi Rönnemaa, Tapani Nuutila, Pirjo Nummenmaa, Lauri Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title | Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title_full | Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title_fullStr | Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title_full_unstemmed | Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title_short | Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability |
title_sort | obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and cb(1) receptor availability |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794779/ https://www.ncbi.nlm.nih.gov/pubmed/34728775 http://dx.doi.org/10.1038/s41366-021-00996-y |
work_keys_str_mv | AT kantonentatu obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT pekkarinenlaura obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT karjalainentomi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT buccimarco obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT kalliokoskikari obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT haaparantasolinmerja obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT aarniorichard obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT dickensalexm obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT voneykenannie obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT laitinenkirsi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT houttunoora obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT kirjavainenannak obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT helinsemi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT hirvonenjussi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT ronnemaatapani obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT nuutilapirjo obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability AT nummenmaalauri obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability |